Karex Berhad (KLSE: KAREX), the world’s largest condom manufacturer, announced on April 22, 2026, that it will increase prices by up to 30% due to supply chain disruptions from the Iran-Israel conflict, which has restricted access to natural rubber from key Southeast Asian plantations and driven up nitrile butadiene rubber (NBR) costs by 22% since January, according to S&P Global Commodity Insights.
The Bottom Line
- Karex’s price hike could add RM120 million ($26.4 million) in annual revenue if volume remains stable, based on 2024 sales of RM400 million.
- Competitors Ansell (ASX: ANN) and Reckitt Benckiser (LSE: RB.) may gain share in premium segments, though Ansell’s Q1 2026 EBITDA margin fell 180 bps to 22.1% amid similar input cost pressures.
- Global condom market inflation could contribute 0.03 percentage points to headline CPI in emerging markets, where contraceptives represent 1.8% of household health spending per UNFPA data.
How Karex’s Price Surge Exposes Fragile Global Rubber Supply Chains
The Iran-Israel conflict, escalating since late 2025, has disrupted shipping lanes through the Strait of Hormuz, increasing freight costs for Malaysian rubber exports by 35% according to Drewry Shipping Consultants. Karex, which sources 60% of its natural rubber from Thailand and Indonesia, faces dual pressure: latex prices have risen 28% YoY to RM8.20/kg (Malaysian Rubber Board), even as synthetic NBR — used in 40% of its production — has spiked due to U.S. Sanctions on Iranian petrochemical exports, a key feedstock for acrylonitrile. This has pushed Karex’s cost of goods sold (COGS) to 68% of revenue in Q1 2026, up from 61% in the prior year, per its Bursa Malaysia filing.
Analysts at Maybank Investment Bank note that Karex’s gross margin contracted to 32% in Q1 2026 from 39% a year earlier, forcing the price adjustment. “The company has limited pricing power in volume-driven emerging markets,” said
Lee Wei Chen, senior analyst at Maybank IB
, “but its dominance in institutional channels — supplying 70% of UNFPA’s condom procurement — allows it to pass costs to humanitarian buyers with inelastic demand.”
Competitor Reactions and Market Share Shifts in the Global Contraceptives Landscape
While Karex controls 25% of the global condom market by volume, rivals are positioning to capture share in price-sensitive segments. Ansell, which derives 15% of revenue from sexual health products, reported flat condom sales in Q1 2026 despite a 12% price increase, indicating volume elasticity. Reckitt Benckiser, maker of Durex, maintained prices in its Q1 update but acknowledged “input cost headwinds” and is accelerating automation at its Thailand plant to reduce labor dependency.
A shift toward female-controlled contraceptives may further complicate demand dynamics. According to UNFPA’s 2025 report, intrauterine device (IUD) adoption grew 9% annually in sub-Saharan Africa between 2020–2024, potentially offsetting some condom demand volatility. However, in regions like Pakistan and Nigeria — where Karex has 40% market share — cultural barriers to alternative methods keep condom demand relatively inelastic, supporting pricing power.
Macroeconomic Ripple Effects: Inflation, Healthcare Budgets, and Forex Volatility
The price increase carries measurable macroeconomic implications. In Malaysia, where Karex contributes 0.15% to national GDP, the hike could add 0.02 percentage points to producer price index (PPI) inflation, per Department of Statistics Malaysia modeling. More significantly, in frontier markets like Yemen and Sudan — where humanitarian aid funds 90% of condom purchases — the price rise may strain already constrained health budgets. The World Bank estimates that a 10% increase in essential medical supplies costs can reduce treatment access by 3–5% in low-income economies.
Currency movements similarly play a role. The Malaysian ringgit has weakened 8% against the U.S. Dollar since January 2026 (Bank Negara Malaysia), increasing the local-currency cost of dollar-denominated NBR imports. Karex reported that 30% of its raw material costs are USD-exposed, and while it hedges 50% of forecasted exposure, unhedged positions contributed to a RM15 million forex loss in Q1 2026.
| Metric | Karex Q1 2026 | Karex Q1 2025 | Ansell Q1 2026 |
|---|---|---|---|
| Revenue (local currency) | RM105 million | RM98 million | AUD 1.42 billion |
| COGS Margin | 68% | 61% | 54% |
| Gross Margin | 32% | 39% | 46% |
| EBITDA Margin | 24.1% | 30.5% | 22.1% |
| Price Increase Announced | Up to 30% | None | 12% (condom segment) |
The Path Forward: Hedging, Automation, and Demand Resilience
Karex is responding with a dual strategy: accelerating automation at its Port Klang facility to reduce labor dependency by 2027 and expanding NBR sourcing to Vietnam and India to diversify beyond Malaysian supply chains. Capital expenditure rose to RM45 million in Q1 2026 (up 60% YoY) as part of this initiative. The company also renewed its 3-year hedging program for natural rubber through Bursa Malaysia Derivatives, covering 70% of 2026 latex needs at an average strike of RM7.80/kg.
Despite near-term margin pressure, demand fundamentals remain supportive. The global contraceptives market is projected to grow at 4.2% CAGR through 2030 (Grand View Research), driven by rising HIV prevention funding and youth population growth in Asia, and Africa. Karex’s CEO, Goh Miah Kiat, affirmed in a Bloomberg interview that “volume decline has been minimal (<2%) in markets where we’ve implemented tiered pricing,” suggesting that the 30% increase may be applied selectively to premium and institutional channels.
For investors, the key monitor is whether Karex can stabilize gross margins above 35% by Q3 2026. If input costs persist, further price adjustments may be necessary — but with Ansell and Reckitt already adjusting, the window for unilateral action may be closing.
Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.
